Effects of the SGLT‐2 inhibitor dapagliflozin on glomerular and tubular injury markers

The mechanisms by which SGLT‐2 inhibitors lower albuminuria are incompletely understood. We assessed in a post‐hoc analysis of a cross‐over trial the effects of the SGLT2 inhibitor dapagliflozin on glomerular markers (IgG to IgG4 and IgG to albumin), tubular markers (urinary KIM‐1, NGAL and LFABP) a...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Diabetes Obes Metab
Autors principals: Dekkers, Claire C. J., Petrykiv, Sergei, Laverman, Gozewijn D., Cherney, David Z., Gansevoort, Ron T., Heerspink, Hiddo J. L.
Format: Artigo
Idioma:Inglês
Publicat: Blackwell Publishing Ltd 2018
Matèries:
Brief Reports
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6055757/
https://ncbi.nlm.nih.gov/pubmed/29573529
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.13301
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars